Financial Survey: Repligen (RGEN) versus The Competition

Repligen (NASDAQ:RGEN) is one of 109 public companies in the “Life Sciences Tools & Services” industry, but how does it compare to its peers? We will compare Repligen to related businesses based on the strength of its risk, institutional ownership, profitability, analyst recommendations, dividends, earnings and valuation.

Risk & Volatility

Repligen has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Repligen’s peers have a beta of 0.94, indicating that their average stock price is 6% less volatile than the S&P 500.

Earnings & Valuation

This table compares Repligen and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Repligen	$738.26 million	$48.89 million	-826.14
Repligen Competitors	$2.26 billion	$55.88 billion	-7.92

Repligen’s peers have higher revenue and earnings than Repligen. Repligen is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

97.6% of Repligen shares are held by institutional investors. Comparatively, 53.5% of shares of all “Life Sciences Tools & Services” companies are held by institutional investors. 0.6% of Repligen shares are held by insiders. Comparatively, 15.0% of shares of all “Life Sciences Tools & Services” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings for Repligen and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	1	3	12	2	2.83
Repligen Competitors	953	3175	5509	178	2.50

Repligen presently has a consensus target price of $178.57, suggesting a potential upside of 2.93%. As a group, “Life Sciences Tools & Services” companies have a potential downside of 2.53%. Given Repligen’s stronger consensus rating and higher possible upside, equities analysts clearly believe Repligen is more favorable than its peers.

Profitability

This table compares Repligen and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Repligen	-1.47%	5.49%	3.93%
Repligen Competitors	-540.59%	-166.46%	-13.58%

Summary

Repligen beats its peers on 9 of the 13 factors compared.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.